Erythropoietin stimulating factors in CML – pro
Anemia occurs in many patients with chronic myeloid leukemia (CML) who are treated with imatinib. There are studies that concluded that erythropoietin is safe and effective in patients in chronic-phase CML who develop anemia with imatinib therapy. Santos 2011 showed that it is a safe therapy as well.
Steegmann JL, Baccarani M, Breccia M, Casado LF, García-Gutiérrez V, Hochhaus A, Kim DW, Kim TD, Khoury HJ, Le Coutre P, et al.European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia. Leukemia. 2016 Aug; 30(8):1648-71. Epub 2016 Apr 28.
Cortes J et al, Erythropoietin is effective in improving the anemia induced by imatinib mesylate therapy in patients with chronic myeloid leukemia in chronic phase. Cancer. 2004 Jun 1;100(11):2396-402.
Santos FP, Alvarado Y, Kantarjian H, et al. Long-term prognostic impact of the use of erythropoietic-stimulating agents in patients with chronic myeloid leukemia in chronic phase treated with imatinib. Cancer. 2011;117(5):982991.